TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER (TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER).
Amino acids provide substrates for protein synthesis and energy metabolism; dextrose provides caloric support.
| Metabolism | Amino acids are metabolized via transamination, deamination, and urea cycle; dextrose undergoes glycolysis and oxidative phosphorylation. |
| Excretion | Renal: 100% of infused amino acids and dextrose are metabolized or excreted; no intact drug excretion. Biliary/fecal: negligible. |
| Half-life | Not applicable; components are endogenous substances with rapid metabolic turnover. Exogenous amino acids have half-lives of minutes to hours, dextrose ~1-2 hours. |
| Protein binding | Amino acids: minimal to moderate binding to albumin and globulins (variable). Dextrose: not protein bound. |
| Volume of Distribution | Amino acids: approximate Vd 0.3-0.4 L/kg (total body water). Dextrose: Vd ~0.2 L/kg (extracellular fluid). |
| Bioavailability | 100% via intravenous route; not administered by other routes. |
| Onset of Action | Immediate upon IV infusion; metabolic effects begin within minutes as amino acids and glucose enter circulation. |
| Duration of Action | Duration is dependent on infusion rate and metabolic demand; continuous infusion maintains steady state; effects cease shortly after infusion stops. |
| Molecular Weight | Weighted average: amino acids ~75-200 Da; dextrose 180.16 Da |
Intravenous infusion. Typical adult dose: 500 mL to 1000 mL per day administered at a rate not exceeding 5 mL/kg/hour, based on protein and electrolyte requirements.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in anuria or oliguria. In renal impairment, dose adjustment required based on GFR: GFR 10-30 mL/min: reduce frequency to every 12-24 hours; GFR <10 mL/min: avoid use or use with extreme caution, typically at reduced volume. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Contraindicated or use with extreme caution, typically at 25% of normal dose. |
| Pediatric use | Weight-based dosing: 2-3 g of amino acids per kg per day (corresponding to approximately 73-109 mL/kg/day of Travasol 2.75%). Adjust according to metabolic requirements and clinical response; maximum infusion rate 0.1 g amino acids/kg/hour. |
| Geriatric use | Use with caution due to decreased renal and hepatic function; start at lower end of dosing range and adjust based on fluid and electrolyte status, monitoring for signs of fluid overload. |
| 1st trimester | TRAVASOL 2.75% IN DEXTROSE 5% is a combination of amino acids and dextrose used for parenteral nutrition. No well-controlled studies in pregnant women. Should be used during pregnancy only if clearly needed and under medical supervision. |
| 2nd trimester | Limited data; may be used if maternal nutritional status requires parenteral support. Monitor maternal and fetal status. |
| 3rd trimester | May be used if indicated for maternal nutrition, but consider potential fluid and electrolyte imbalances in the neonate. |
Clinical note
Comprehensive clinical and safety monograph for TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER (TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER).
| Placental transfer | Amino acids and dextrose are actively transported across the placenta. Exogenous administration may increase fetal levels, but is generally considered safe when maternal nutrition is deficient. |
| Breastfeeding | TRAVASOL 2.75% IN DEXTROSE 5% components are endogenous substances normally present in breast milk. Exogenous administration may minimally increase levels; however, due to low risk, use is likely compatible with breastfeeding. Monitor infant for any adverse effects. |
| Lactation Rating | L2 (Limited data - probably compatible) |
| Teratogenic Risk | No adequate studies in pregnant women. In animal studies, no teratogenic effects observed at clinical doses. Risk cannot be excluded. Use during pregnancy only if clearly needed. |
| Fetal Monitoring | Monitor maternal electrolytes, fluid balance, glucose levels, and signs of infection. Fetal monitoring for growth and well-being if used long-term. |
| Fertility Effects | No known effects on fertility based on available data. |
■ FDA Black Box Warning
Solutions are hypertonic; infusion into peripheral veins may cause thrombophlebitis. Central venous administration is preferred.
| Serious Effects |
Hypersensitivity to any componentSevere hyperglycemia or hyperosmolar comaSevere hepatic failure or hepatic comaSevere renal failure without dialysis supportInborn errors of amino acid metabolismSevere fluid overload or pulmonary edema
| Precautions | Risk of hyperglycemia, electrolyte imbalances, catheter-related infections, and metabolic acidosis. Monitor serum glucose, electrolytes, and acid-base status. |
| Food/Dietary | No specific food interactions, as TRAVASOL is administered intravenously and bypasses the gastrointestinal tract. Patients should follow their prescribed oral diet if applicable, but there are no restrictions with food. However, concurrent oral intake may affect overall nutritional balance; thus, dietary adjustments should be made based on total nutrient intake. |
| Clinical Pearls | TRAVASOL 2.75% IN DEXTROSE 5% is a peripheral parenteral nutrition solution providing a moderate amino acid load and minimal dextrose. It is contraindicated in patients with severe hepatic disease, hyperammonemia, or uncorrected metabolic acidosis. Use with caution in renal insufficiency due to risk of fluid overload and electrolyte disturbances. Administer via central line only if osmolarity exceeds 900 mOsm/L; this solution typically has an osmolarity of ~850 mOsm/L, allowing peripheral administration with careful monitoring for thrombophlebitis. Do not add medications directly to the bag; use a dedicated Y-site with compatible additives. Monitor serum electrolytes, blood glucose, liver function, and ammonia levels daily. Discontinue if signs of catheter infection or air embolism appear. |
| Patient Advice | TRAVASOL is a liquid nutrition given through a vein for patients who cannot eat normally. It provides proteins and sugar (dextrose) to help your body heal and maintain strength. · You or your caregiver will be trained on how to use the IV pump and tubing correctly. Always wash hands before handling the line. · Check the plastic bag for cloudiness, particles, or leaks before use. If any are present, do not use and contact your healthcare provider. · Do not stop the infusion suddenly if you feel burning, swelling, or redness at the IV site. Immediately call the nurse or doctor. · You may need to have blood tests regularly to check your sugar, electrolytes, and liver function while on this nutrition. · Avoid drinking alcohol or taking any other medications without your doctor's approval, as they may interfere with this solution. |
Loading safety data…